TABLE 5.
NeuroBlate (Monteris Medical) Prognostic Groups Compared With Biopsy Control
| Groupc | n | Median survival or cumulative incidence in 12 mo | P valuec (compared to biopsy after adjustment) |
|---|---|---|---|
| OSa | |||
| Biopsy | 24 | 15.8 | |
| Favorable | 8 | 10.1 | .64 |
| Intermediate | 9 | 21.4 | .80 |
| Unfavorable | 7 | 14.4 | .78 |
| DSOSb | |||
| Biopsy | 24 | 31% ± 1% | |
| Favorable | 8 | 25% ± 3% | .033 (in favor of LA) |
| Intermediate | 9 | 13% ± 2% | .31 |
| Unfavorable | 7 | 40% ± 6% | .43 |
| PFSa | |||
| Biopsy | 24 | 5.97 | |
| Favorable | 8 | 8.20 | .21 |
| Intermediate | 9 | 4.52 | .12 |
| Unfavorable | 7 | 3.28 | .001 (in favor of biopsy) |
| DSPFSb | |||
| Biopsy | 24 | 63% ± 1% | |
| Favorable | 8 | 25% ± 3% | .05 |
| Intermediate | 9 | 88% ± 3% | .17 |
| Unfavorable | 7 | 100% ± 2% | <.001 (in favor of biopsy) |
LA: laser ablation
aLog rank test comparisons to biopsy only
bGray's test for comparisons to biopsy only
cAdjusted for age (≤ 70 yr vs > 70 yr), gender, tumor location and tumor volume (≤ 11 cc vs > 11 cc)